A tetravalent bispecific antibody that binds CD30 on tumor cells and CD16A on NK cells (AFM13) has also been tested in a phase I trial for patients with relapsed/refractory Hodgkin lymphoma (29). The gene discussed is FCGR3A; the disease is neoplasm.